Sonic hedgehog pathway inhibitor mitigates mouse hepatocellular carcinoma

Kuo Shyang Jeng, Chi Juei Jeng, Wen Juei Jeng, I. Shyan Sheen, Chiung Fang Chang, Hsin I. Hsiau, Zih Hang Hung, Ming Che Yu, Fang Yu Chang

研究成果: 雜誌貢獻文章同行評審

17 引文 斯高帕斯(Scopus)


Background Hepatocellular carcinoma (HCC) is a leading cause of death in Asian countries. Sonic hedgehog (Shh) pathway plays a role in hepatocarcinogenesis. We investigated the treatment effect of mouse HCC with Shh inhibitor GDC-0449. Methods Mouse hepatoma ML-1 cells were implanted in B6 mice. Fifteen days later, GDC-0449 (vismodegib), antagonist of smoothened, was used to treat HCC-bearing mice. The tumor size and liver histopathological features were analyzed, as well as gene expression in Shh pathways. Results GDC-0449 treatment effectively reduced tumor size and cell infiltration of the HCC in mice. Gene expression of Shh pathway molecules was altered, including upregulated Shh expression and downregulated smoothened expression in tumor fractions after GDC-0449 treatment. Conclusion GDC-0449 could effectively mitigate HCC growth in vivo.

頁(從 - 到)554-560
期刊American Journal of Surgery
出版狀態已發佈 - 1月 1 2015

ASJC Scopus subject areas

  • 手術


深入研究「Sonic hedgehog pathway inhibitor mitigates mouse hepatocellular carcinoma」主題。共同形成了獨特的指紋。